Format

Send to

Choose Destination
Curr Opin Pharmacol. 2002 Aug;2(4):382-7.

Epidermal growth factor receptor tyrosine kinase inhibitors.

Author information

1
Cancer & Infection Research, AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Cheshire SK10 4TG, Macclesfield, UK.

Abstract

Clinical trials of selective small-molecule inhibitors of epidermal growth factor receptor tyrosine kinase activity have shown that these targeted inhibitors of proliferative signal transduction provide well-tolerated antitumour activity in patients. Preclinical pharmacology studies illustrate the potential use of these new cancer therapeutics in combination with chemotherapy, radiotherapy and hormone therapy, and in chemoprevention, in a spectrum of solid human tumours.

PMID:
12127870
DOI:
10.1016/s1471-4892(02)00183-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center